Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
28 hedge funds and large institutions have $31.3M invested in Astria Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
31% more capital invested
Capital invested by funds: $23.9M → $31.3M (+$7.42M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
8% more funds holding
Funds holding: 26 → 28 (+2)
1.13% more ownership
Funds ownership: 6.34% → 7.48% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$659K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$443K |
| 3 |
Renaissance Technologies
New York
|
+$291K |
| 4 |
BlackRock
New York
|
+$284K |
| 5 |
JP Morgan Chase
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$350K |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$330K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$113K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$89K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$60.3K |
ATXS Hedge Fund Activity: Q4 2019 in Review
28 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2019, worth a combined $31.3M — up 31% from $23.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ATXS positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $659K. The largest seller was Federated Hermes, cutting an estimated $350K.
- 28 institutional investors held Astria Therapeutics (ATXS) as of Q4 2019, up from 26 in Q3 2019.
- Funds reported $31.3M of Astria Therapeutics stock for Q4 2019, up 31% quarter-over-quarter.
- 9 funds opened new Astria Therapeutics positions in Q4 2019 and 7 closed out, a net change of +2 holders.
- The largest Astria Therapeutics buyer in Q4 2019 was Alyeska Investment Group, an estimated $659K added.
- The largest Astria Therapeutics seller in Q4 2019 was Federated Hermes, an estimated $350K sold.
Based on aggregated 13F filings for Q4 2019.